Infectious Causes of Cancer

You have full text access to this OnlineOpen article

Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: Bases for improved immunotherapy

  1. Debora Martorelli1,
  2. Karim Houali2,
  3. Laura Caggiari3,
  4. Emanuela Vaccher4,
  5. Luigi Barzan5,
  6. Giovanni Franchin6,
  7. Annunziata Gloghini7,
  8. Alessandro Pavan1,
  9. Alessandro Da Ponte8,
  10. Rosa Maria Tedeschi9,
  11. Valli De Re3,
  12. Antonino Carbone10,
  13. Tadamasa Ooka2,
  14. Paolo De Paoli9,
  15. Riccardo Dolcetti1,†,*

Article first published online: 10 JUN 2008

DOI: 10.1002/ijc.23621

Issue

International Journal of Cancer

International Journal of Cancer

Volume 123, Issue 5, pages 1100–1107, 1 September 2008

Additional Information

How to Cite

Martorelli, D., Houali, K., Caggiari, L., Vaccher, E., Barzan, L., Franchin, G., Gloghini, A., Pavan, A., Da Ponte, A., Tedeschi, R. M., De Re, V., Carbone, A., Ooka, T., De Paoli, P. and Dolcetti, R. (2008), Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: Bases for improved immunotherapy. Int. J. Cancer, 123: 1100–1107. doi: 10.1002/ijc.23621

Author Information

  1. 1

    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, IRCCS-National Cancer Institute, Aviano (PN), Italy

  2. 2

    Laboratoire de Virologie Moléculaire, Faculté de Médecine Laennec, Université Claude Bernard Lyon-1, Lyon, France

  3. 3

    Clinical and Experimental Pharmacology, Centro di Riferimento Oncologico, IRCCS-National Cancer Institute, Aviano (PN), Italy

  4. 4

    Division of Medical Oncology A, Centro di Riferimento Oncologico, IRCCS-National Cancer Institute, Aviano (PN), Italy

  5. 5

    Head and Neck Department, Azienda Ospedaliera, Pordenone, Italy

  6. 6

    Department of Radiotherapy, Centro di Riferimento Oncologico, IRCCS-National Cancer Institute, Aviano (PN), Italy

  7. 7

    Department of Pathology, Diagnostic Immunohistochemistry and Molecular Pathology Unit, Centro di Riferimento Oncologico, IRCCS-National Cancer Institute, Aviano (PN), Italy

  8. 8

    Blood Bank, Centro di Riferimento Oncologico, IRCCS-National Cancer Institute, Aviano (PN), Italy

  9. 9

    Microbiology-Immunology and Virology Unit, Centro di Riferimento Oncologico, IRCCS-National Cancer Institute, Aviano (PN), Italy

  10. 10

    Department of Pathology, Istituto Nazionale Tumori, Milan, Italy

  1. †

    Fax: +39-0434-659659

*Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico-IRCCS, National Cancer Institute, Via Franco Gallini 2, 33081, Aviano (PN), Italy

Publication History

  1. Issue published online: 17 JUN 2008
  2. Article first published online: 10 JUN 2008
  3. Manuscript Accepted: 13 MAR 2008
  4. Manuscript Received: 28 DEC 2007

Funded by

  • European Community. Grant Number: 037874
  • Italian Ministry of Health

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (231K)

References

  • 1
    International Agency for Research on Cancer. Epstein-Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8.IARC monographs on the evaluation of carcinogenic risks to humans. Vol 70. Lyon, France: WHO, 1997.
  • 2
    Dolcetti R,Menezes J. Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: new immunobiological and molecular insights on a long-standing etiopathogenic association. Adv Cancer Res 2003; 87: 127–57.
  • 3
    Rickinson AB,Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997; 15: 405–31.
  • 4
    Khanna R,Burrows SR,Nicholls J,Poulsen LM. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur J Immunol 1998; 28: 451–8.
    Direct Link:
  • 5
    Lee SP,Chan AT,Cheung ST,Thomas WA,CroomCarter D,Dawson CW,Tsai CH,Leung SF,Johnson PJ,Huang DP. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. J Immunol 2000; 165: 573–82.
  • 6
    Lin CL,Lo WF,Lee TH,Ren Y,Hwang SL,Cheng YF,Chen CL,Chang YS,Lee SP,Rickinson AB,Tam PK. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 2002; 62: 6952–8.
  • 7
    Comoli P,Pedrazzoli P,Maccario R,Basso S,Carminati O,Labirio M,Schiavo R,Secondino S,Frasson C,Perotti C,Moroni M,Locatelli F, et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 2005; 23: 8942–9.
  • 8
    Straathof KC,Bollard CM,Popat U,Huls MH,Lopez T,Morriss MC,Gresik MV,Gee AP,Russell HV,Brenner MK,Rooney CM,Heslop HE. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005; 105: 1898–904.
  • 9
    Decaussin G,Sbih-Lammali F,De Turenne-Tessier M,Bouguermouh A,Ooka T. Expression of BARF1 gene encoded by Epstein-Barr virus in nasopharyngeal carcinoma biopsies. Cancer Res 2000; 60: 5584–8.
  • 10
    Seto E,Yang L,Middeldorp J,Sheen TS,Chen JY,Fukayama M,Eizuru Y,Ooka T,Takada K. Epstein-Barr Virus (EBV)-encoded BARF1 gene is expressed in nasopharyngeal carcinoma and EBV-associated gastric carcinoma tissues in the absence of lytic gene expression. J Med Virol 2005; 76: 82–8.
    Direct Link:
  • 11
    Ooka T. Malignant transformation and immortalization assays in animal cells transfected with the BARF1 gene. Methods Mol Biol 2001; 174: 147–54.
  • 12
    Wei MX,de Turenne-Tessier M,Decaussin G,Benet G,Ooka T. Establishment of a monkey kidney epithelial cell line with the BARF1 open reading frame from Epstein-Barr virus. Oncogene 1997; 14: 3073–81.
  • 13
    Wei MX,Ooka T. A transforming function of the BARF1 gene encoded by Epstein-Barr virus. EMBO J 1989; 8: 2897–903.
  • 14
    Wei MX,Moulin JC,Deacussin G,Berger F,Ooka T. Expression and tumorigenicity of the Epstein-Barr virus BARF1 gene in human Louckes B-lymphocyte cell line. Cancer Res 1994; 54: 1843–8.
  • 15
    Strockbine LD,Cohen JI,Farrah T,Lyman SD,Wagener F,DuBose RF,Armitage RJ,Spriggs MK. The Epstein-Barr virus BARF1 gene encodes a novel, soluble colony-stimulating factor-1 receptor. J Virol 1998; 72: 4015–21.
  • 16
    Sall A,Caserta S,Jolicoeur P,Franqueville L,de Turenne-Tessier M,Ooka T. Mitogenic activity of Epstein-Barr virus-encoded BARF1 protein. Oncogene 2004; 23: 4938–44.
  • 17
    de Turenne-Tessier M,Jolicoeur P,Middeldorp JM,Ooka T. Expression and analysis of the Epstein-Barr virus BARF1-encoded protein from a tetracycline-regulatable adenovirus system. Virus Res 2005; 109: 9–18.
  • 18
    Cohen JI,Lekstrom K. Epstein-Barr virus BARF1 protein is dispensable for B-cell transformation and inhibits alpha interferon secretion from mononuclear cells. J Virol 1999; 73: 7627–32.
  • 19
    Tanner JE,Wei MX,Alfieri C,Ahmad A,Taylor P,Ooka T,Menezes J. Antibody and antibody-dependent cellular cytotoxicity responses against the BamHI A rightward open-reading frame-1 protein of Epstein-Barr virus (EBV) in EBV-associated disorders. J Infect Dis 1997; 175: 38–46.
  • 20
    Barnes L,Eveson JW,Reichart P,Sidransky D. World Health Organization classification of tumours pathology and genetics of head and neck tumours. Lyon: IARC Press, 2005. 85–97.
  • 21
    Sheng W,Decaussin G,Sumner S,Ooka T. N-terminal domain of BARF1 gene encoded by Epstein-Barr virus is essential for malignant transformation of rodent fibroblasts and activation of BCL-2. Oncogene 2001; 20: 1176–85.
  • 22
    Mould RF,Tai TH. Nasopharyngeal carcinoma: treatments and outcomes in the 20th century. Br J Radiol 2002; 75: 307–39.
  • 23
    Zur Hausen A,Brink AA,Craanen ME,Middeldorp JM,Meijer CJ,van den Brule AJ. Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. Cancer Res 2000; 60: 2745–8.
  • 24
    Dionne SO,Smith MH,Marincola FM,Lake DF. Functional characterization of CTL against gp100 altered peptide ligands. Cancer Immunol Immunother 2003; 52: 199–206.
  • 25
    Gross DA,Graff-Dubois S,Opolon P,Cornet S,Alves P,Bennaceur-Griscelli A,Faure O,Guillaume P,Firat H,Chouaib S,Lemonnier FA,Davoust J, et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 2004; 113: 425–33.
  • 26
    Steven NM,Annels NE,Kumar A,Leese AM,Kurilla MG,Rickinson AB. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr Virus-induced cytotoxic T cell response. J Exp Med 1997; 185: 1605–17.
  • 27
    Pudney VA,Leese AM,Rickinson AB,Hislop AD. CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J Exp Med 2005; 201: 349–60.
  • 28
    Zhang JX,Chen HL,Zong YS,Chan KH,Middeldrop JM,Sham JS,Griffin BE,Ng MH. Epstein-Barr virus expression within keratinizing nasopharyngeal carcinoma. J Med Virol 1998; 55: 227–33.
    Direct Link:
  • 29
    Whitney BM,Chan AT,Rickinson AB,Lee SP,Lin CK,Johnson PJ. Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients. J Med Virol 2002; 67: 359–63.
    Direct Link:
View Full Article (HTML) Get PDF (231K)